BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 2, 2009--
Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH) today announced the appointment of Dr. Mark Elliott Brecher
as Chief Medical Officer.
Dr. Brecher is a leader in the field of pathology, with research
published in a wide variety of journals including the New England
Journal of Medicine, The Lancet and the Mayo Clinic Proceedings. Prior
to joining LabCorp, Dr. Brecher served as Vice Chair of the Department
of Pathology and Laboratory Medicine at the McLendon Clinical
Laboratories, University of North Carolina Hospitals.
“Dr. Brecher is a well-respected clinician, researcher, and leader in
the field of pathology,” said David P. King, Chief Executive Officer.
“His appointment underscores LabCorp’s commitment to clinical and
scientific leadership.”
Dr. Brecher is a member of the editorial boards of Transfusion and Blood
Therapies in Medicine and is an associate editor of the Journal of
Clinical Apheresis. He is the immediate past chair of the Department of
Health and Human Services Advisory Committee on Blood Safety and
Availability and a past president of the American Society for Apheresis.
About LabCorp®
Laboratory Corporation of America® Holdings, a S&P 500
company, is a pioneer in commercializing new diagnostic technologies and
the first in its industry to embrace genomic testing. With annual
revenues of $4.5 billion in 2008, over 28,000 employees worldwide, and
more than 220,000 clients, LabCorp offers clinical assays ranging from
routine blood analyses to HIV and genomic testing. LabCorp combines its
expertise in innovative clinical testing technology with its Centers of
Excellence: The Center for Molecular Biology and Pathology, National
Genetics Institute, Inc., ViroMed Laboratories, Inc., The Center for
Esoteric Testing, Litholink Corporation, DIANON Systems, Inc., US
LABS, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and
Cytometry Associates laboratories. LabCorp conducts clinical trial
testing through its Esoterix Clinical Trials Services division. LabCorp
clients include physicians, government agencies, managed care
organizations, hospitals, clinical labs, and pharmaceutical companies.
To learn more about our organization, visit our Web site at: www.labcorp.com.
Each of the above forward-looking statements is subject to change
based on various important factors, including without limitation,
competitive actions in the marketplace and adverse actions of
governmental and other third-party payors. Actual results could
differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for
the year ended December 31, 2008, and subsequent SEC filings.
Source: Laboratory Corporation of America® Holdings
Laboratory Corporation of America® Holdings
Investor/Media
Contact:
Bill Bonello – 336-436-7732
Company
Information: www.labcorp.com
